News&Media

Boost Beyond Boundaries

Press Release

Astrogen, inc. Receives 18th Folia Award for Outstanding Clinical Research in Autism Spectrum Disorder

253 2026-06-19
Astrogen, inc. Receives 18th Folia Award for Outstanding Clinical Research in Autism Spectrum Disorder
Recognized as the Outstanding Paper Published in "Psychiatry and Clinical Neurosciences"

AST-001 demonstrated efficacy and safety in improving social communication, a core symptom of autism spectrum disorder, in children.
Award ceremony and lecture held at 122nd Annual Conference of Japanese Society of Psychiatry and Neurology, Yokohama, June 2026
 
 


Astrogen, inc., a Korean biotech company, has received the "Folia Award" granted by the international psychiatric journal Psychiatry and Clinical Neurosciences (PCN) for its ASD clinical trial paper.

The Folia Award is given annually to the most outstanding paper published in PCN, the journal issued by the Japanese Society of Psychiatry and Neurology (JSPN).
This recognition affirms Astrogen's ASD clinical research achievements in the international psychiatric field. 
The award-winning paper,
"AST-001 versus placebo for social communication in children with autism spectrum disorder:A randomized clinical trial," was published in PCN (Vol. 79, Issue 1) in January 2025.
The study, led by Professor Hyo-Won Kim from Asan Medical Center and Professor Yoo-Sook Joung from Samsung Medical Center, evaluated the efficacy and safety of AST-001 (Speragen Syrup) in children with ASD using a randomized controlled trial (RCT).


The PCN Editorial Committee selected this paper as the recipient of the "18th Folia Award (2025)" and awarded a prize of 100,000 yen.
The research team was invited to the 122nd Annual Conference of the Japanese Society of Psychiatry and Neurology held in Yokohama, Japan from June 18-20, 2026,where CEO Hwang Su-kyeong, who led the research initiative and represented Astrogen, delivered the Award Lecture presenting the key findings and clinical significance of the study.




CEO Hwang Su-kyeong stated:
 "We are honored to receive this award from PCN, an institution with a long history in psychiatry. Speragen has submitted an application for product approval to Korea's Ministry of Food and Drug Safety (MFDS) and we await the results. We hope this award positively influences discussions on Speragen's development and approval. Japan is a key strategic market, and we are actively pursuing development and commercialization opportunities to deliver Speragen to patients and families as quickly as possible."

Following this recognition, the research team has been formally invited by the PCN Editorial Committee to contribute an invited review article, "PCN Frontier Review," on the latest research trends in autism spectrum disorder.

Astrogen is committed to advancing research in this field while advancing Speragen's development and commercialization efforts in global markets, including Japan.


https://www.businesswire.com/news/home/20260618653883/en
https://www.businesswire.com/news/home/20260618350329/ja